MedTrace Logo

Medico-economic Evaluation of Anti-VEGF Treatments in the Treatment of naïve Age-related Macular Degeneration (AMD): a Model Adapted to the French Context

NCT03577041 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2023-03-22

No results posted yet for this study

Summary

Age-related macular degeneration (AMD) is the leading cause of blindness after 50 years in industrialized countries, compromising daily activities and reducing quality of life. And whose treatment is one of the first health expenditures. Since September 2015, Bevacizumab, which does not have marketing authorization in AMD, has been given a temporary recommendation for use. Studies in other countries have shown that bevacizumab is cost-effective in the treatment of AMD compared to other anti-VEGF therapies used.

Conditions

  • Age-related Macular Degeneration (AMD)

Sponsors & Collaborators

  • Centre Hospitalier Universitaire, Amiens

    lead OTHER

Principal Investigators

  • Sophie BRYSELBOUT, Dr · CHU Amiens

  • Marc MURAINE, Pr · CHU Rouen

  • Xavier ZANLONGHI, Dr · Nantes University Hospital

  • Carl ARNDT · Carl

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-01
Primary Completion
2023-07-01
Completion
2023-07-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03577041 on ClinicalTrials.gov